Japan’s Major Generic Drug Makers Sawai And Towa To Launch Batches Of Products
This article was originally published in PharmAsia News
Executive SummaryJapan's largest generic drug maker Saiwai will launch 34 products after May, including anticancer, ulcer and pollakiuria drugs. The launch is a 7 percent increase compared to last year. Sawai's production capacity also increased by 30 percent compared to 2007. Rival Japanese generic drug maker Towa Pharmaceutical plans to launch 14 products including anti-infection drugs. To promote the products, Towa has increased staff members to provide information to medical facilities. (Click here for more - Japanese language
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.